Where Will Novavax Be in 1 Year?
What a difference a few months make. Vaccine specialist (NASDAQ: NVAX) started the year poorly, continuing with the issues it has encountered since mid-2021.
Those headwinds included the difficulties it faced in launching its COVID vaccine in the U.S. and the significant slowdown in demand for these products, leading to a decline in revenue and earnings for the biotech.
However, several developments have jolted Novavax's stock since January. The company's shares are up by just under 200% this year. Can it keep up that momentum through the next 12 months? Let's find out.
Source Fool.com
Novavax Inc. Aktie
6,89 €
-1,01 %
Aktuell gibt es mit 8 Buy-Einschätzungen und 3 Sell-Einschätzungen ein positives Sentiment für die Novavax Inc. Aktie.
Ein Kursziel von 11 € für Novavax Inc. könnte zu einer Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 6.89 € führen.
